Methods and compositions for the treatment of gliomas
Pharmaceutical compositions of selective EP2 antagonists exemplified by small molecules TG4-155 and TG6-10-1 effective for treating gliomas, and methods for administering the pharmaceutical compositions to treat subjects suffering from disorders characterized by gliomagenesis.
1. A method of treating a subject suffering from malignant glioma, the method comprising administering to the subject a pharmaceutical composition comprising a selective EP2 antagonist selected from the group consisting of TG4-155, TG6-10-1, and combinations thereof, whereby invasion and/or migration of glioma cells is suppressed, thereby treating the subject.
2. The method according to claim 1 , wherein the subject suffers from glioma selected from grade II-IV astrocytoma, oligodendroglioma and oligoastrocytoma.
3. The method according to claim 2 , wherein the glioma is a grade IV astrocytoma selected from primary and secondary glioblastoma (GB).
4. The method according to claim 1 , wherein the subject is human or non-human animal.
5. The method according to claim 1 , wherein the selective EP2 antagonist TG4-155 is defined by the following structure:
6. The method according to claim 1 , wherein the selective EP2 antagonist TG6-10-1 is defined by the following structure:
7. The method according to claim 1 wherein administering comprises via oral, rectal, subcutaneous, intravenous, intramuscular, intranasal or infusive routes.
8. The method according to claim 1 wherein administering comprises administering a dose of between 0.01 and 1000 mg/kg, between 0.1 and 500 mg/kg, between 1 and 250 mg/kg body weight, or 5, 10, 20, 50, 100, 150, 200 or 250 mg/kg body weight of the subject per day in one or multiple doses.